Andrew Grieve is the CEO of Zenabis and he joined Business of Cannabis to talk about their agreement to grow Tantalus Labs genetics on contract as well as their stock offering to current shareholders – which has been the topic of conversation among those…
Read MoreAndrew Grieve is the CEO of Zenabis and he joined Business of Cannabis to talk about their agreement to grow Tantalus Labs genetics on contract as well as their stock…
MoreAndrew Grieve, CEO of Zenabis, joined Jay Rosenthal for BofC Live to talk about their $30 million Prepaid Supply Agreement (PSA) with Tilray.…
MoreOn Wednesday, June 5th – Andrew Grieve, CEO of Zenabis opened the TSX. He joined Business of Cannabis immediately after the opening bell.…
More